AGM/EGMJun 30, 2026, 06:08 AM
Addex Shareholders Approve All Resolutions at Annual General Meeting
AI Summary
Addex Therapeutics announced that its shareholders approved all proposals from the Board of Directors at the 2026 Annual General Meeting with a large majority. Key approvals included the 2025 financial statements, compensation report, and compensation for the board and executive management. Shareholders also re-elected all current board members, including Dr. Vincent Lawton as Chairman, and re-appointed BDO SA as auditors. Amendments to the Articles of Association concerning capital structure were also approved.
Key Highlights
- Shareholders approved all proposals from the Board of Directors at the 2026 Annual General Meeting.
- Approved the 2025 annual report, consolidated and annual financial statements, and compensation report.
- Approved compensation for the board of directors and executive management.
- Granted discharge to board members and executive management for their 2025 activities.
- Dr. Vincent Lawton was re-elected as Chairman and board member, and Dr. Raymond Hill was re-elected as board member.
- Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn, and Dr. Isaac Manke were re-elected as board members.
- BDO SA was re-elected as auditors for the 2026 business year.
- Approved amendments to the Articles of Association related to the capital band and conditional share capital.
Price Impact
More from ADXN